株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

慢性手湿疹(CHE)- 市場の洞察、疫学、および市場予測-2030

Chronic Hand Eczema (CHE) - Market Insights, Epidemiology, and Market Forecast - 2030

発行 DelveInsight Business Research LLP 商品コード 868383
出版日 ページ情報 英文 201 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
慢性手湿疹(CHE)- 市場の洞察、疫学、および市場予測-2030 Chronic Hand Eczema (CHE) - Market Insights, Epidemiology, and Market Forecast - 2030
出版日: 2020年03月01日 ページ情報: 英文 201 Pages
概要

主要7カ国(米国・英国・ドイツ・フランス・イタリア・スペイン・日本)の慢性手湿疹(CHE)の総有病数は422万9,215人、同年の市場規模は7億2,841万米ドルと推計されています。

当レポートでは、主要7カ国(米国・英国・ドイツ・フランス・イタリア・スペイン・日本)の慢性手湿疹(CHE)市場を調査し、疾病の概要や現行の治療法、上市済み治療薬および新薬のプロファイル、主要7カ国の市場動向、疫学的予測、市場規模、重症度・タイプ・年齢別の有病数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 重要洞察

第2章 エグゼクティブサマリー

第3章 慢性手湿疹:市場の概要

  • 市場シェア(実績値)
  • 市場シェア(予測値)

第4章 疫学と調査手法

第5章 関連組織

第6章 慢性手湿疹(CHE):疾病背景と概要

  • イントロダクション
  • 分類
  • 病因
  • 症状
  • 危険因子
  • 病因
  • 重症度と治療反応性の定義
  • 診断
  • 診断アルゴリズム

第7章 疫学と患者数

  • 主な調査結果

第8章 主要7カ国の慢性手湿疹(CHE)の総有病数

第9章 米国の疫学

  • 仮定と根拠
    • 総有病数
    • 有病数:性別
    • 診断数
    • 有病数:重症度別
    • 有病数:タイプ別
    • 有病数:年齢別

第10章 欧州5カ国の疫学

  • ドイツの疫学
    • 総有病数
    • 有病数:性別
    • 診断数
    • 有病数:重症度別
    • 有病数:タイプ別
    • 有病数:年齢別
  • フランスの疫学
  • イタリアの疫学
  • スペインの疫学
  • 英国の疫学

第11章 日本の疫学

  • 仮定と根拠
    • 総有病数
    • 有病数:性別
    • 診断数
    • 有病数:重症度別
    • 有病数:タイプ別
    • 有病数:年齢別

第12章 予防と治療

  • 予防
  • 治療
  • 慢性手湿疹の管理に関するコンセンサスステートメント
  • 手湿疹の予防と治療 - 欧州接触皮膚炎学会(ESCD)ガイドライン
  • 慢性手湿疹の治療アルゴリズム

第13章 アンメットニーズ

第14章 上市済み治療薬

  • Toctino:Basilea Pharmaceutica/ Stiefel Laboratories
    • 医薬品概要
    • 規制のマイルストーン
    • その他の開発動向
    • 安全性と有効性
    • 製品プロファイル

第15章 新薬

  • キークロスコンペティション
  • Delgocitinib:LEO Pharma/Japan Tobacco
    • 医薬品概要
    • その他の開発動向
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル
  • ASN002:Asana Biosciences
  • Dupilumab:Regeneron Pharmaceuticals/Sanofi

第16章 慢性手湿疹:主要7カ国市場の分析

    • 主な調査結果
    • 主要7カ国の市場規模

第17章 米国市場の見通し

  • 市場規模
    • 総市場規模
    • 市場規模:治療薬別

第18章 欧州5カ国市場の見通し

  • ドイツ市場
    • 総市場規模
    • 市場規模:治療薬別
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場

第19章 日本市場の見通し

  • 市場規模
    • 総市場規模
    • 市場規模:治療薬別

第20章 償還制度

  • 現在および将来の治療のためのアクセスと償還制度の概要
    • 現在の治療
    • 将来の治療

第21章 市場の成長要因

第22章 市場の障壁

第23章 SWOT分析

第24章 症例報告

第25章 キーオピニオンリーダーの見解

第26章 付録

第27章 調査手法

第28章 DelveInsightのサービス内容

第29章 免責事項

第30章 DelveInsightについて

図表

List of Tables

  • Table 1 Classification of Hand Eczema
  • Table 2 Definition of subtypes of hand eczema
  • Table 3 Etiological classification of Hand Eczema
  • Table 4 Morphological classification of Hand Eczema
  • Table 5 Characteristics of the various sub diagnostic groups
  • Table 6 Subgroups of hand eczema and definitions
  • Table 7 Risk factors for the development of HE
  • Table 8 Physician's global assessment for chronic hand eczema
  • Table 9 Modified total lesion-symptom score
  • Table 10 Scoring of the patch test according to ICDRG recommendations
  • Table 11 Diagnostic Evaluation of Hand Eczema
  • Table 12 Signs and symptoms of superficially similar lesions of the hand eczema
  • Table 13 Recommendations for the Classification and diagnosis of Hand Eczema
  • Table 14 Total Prevalent Cases of Chronic Hand Eczema in the 7MM (2017-2030)
  • Table 15 Total Prevalent Cases of Chronic Hand Eczema in the US (2017-2030)
  • Table 16 Gender-Specific Cases of CHE in the US (2017-2030)
  • Table 17 Diagnosed Cases of Chronic Hand Eczema in the US (2017-2030)
  • Table 18 Severity Specific Cases of CHE in the US (2017-2030)
  • Table 19 Subgroup Specific Cases of CHE in the US (2017-2030)
  • Table 20 Age-Specific Cases of CHE in the US (2017-2030)
  • Table 21 Total Prevalent Cases of Chronic Hand Eczema in Germany (2017-2030)
  • Table 22 Gender-Specific Cases of CHE in Germany (2017-2030)
  • Table 23 Diagnosed Cases of Chronic Hand Eczema in Germany (2017-2030)
  • Table 24 Severity Specific Cases of CHE in Germany (2017-2030)
  • Table 25 Subgroup Specific Cases of CHE in Germany (2017-2030)
  • Table 26 Age-Specific Cases of CHE in Germany (2017-2030)
  • Table 27 Total Prevalent Cases of Chronic Hand Eczema in France (2017-2030)
  • Table 28 Gender-Specific Cases of CHE in France (2017-2030)
  • Table 29 Diagnosed Cases of Chronic Hand Eczema in France (2017-2030)
  • Table 30 Severity Specific Cases of CHE in France (2017-2030)
  • Table 31 Subgroup Specific Cases of CHE in France (2017-2030)
  • Table 32 Age-Specific Cases of CHE in France (2017-2030)
  • Table 33 Total Prevalent Cases of Chronic Hand Eczema in Italy (2017-2030)
  • Table 34 Gender-Specific Cases of CHE in Italy (2017-2030)
  • Table 35 Diagnosed Cases of Chronic Hand Eczema in Italy (2017-2030)
  • Table 36 Severity Specific Cases of CHE in Italy (2017-2030)
  • Table 37 Subgroup Specific Cases of CHE in Italy (2017-2030)
  • Table 38 Age-Specific Cases of CHE in Italy (2017-2030)
  • Table 39 Total Prevalent Cases of Chronic Hand Eczema in Spain (2017-2030)
  • Table 40 Gender-Specific Cases of CHE in Spain (2017-2030)
  • Table 41 Diagnosed Cases of Chronic Hand Eczema in Spain (2017-2030)
  • Table 42 Severity Specific Cases of CHE in Spain (2017-2030)
  • Table 43 Subgroup Specific Cases of CHE in Spain (2017-2030)
  • Table 44 Age-Specific Cases of CHE in Spain (2017-2030)
  • Table 45 Total Prevalent Cases of Chronic Hand Eczema in the UK (2017-2030)
  • Table 46 Gender-Specific Cases of CHE in the UK (2017-2030)
  • Table 47 Diagnosed Cases of Chronic Hand Eczema in the UK (2017-2030)
  • Table 48 Severity Specific Cases of CHE in the UK (2017-2030)
  • Table 49 Subgroup Specific Cases of CHE in the UK (2017-2030)
  • Table 50 Age-Specific Cases of CHE in the UK (2017-2030)
  • Table 51 Total Prevalent Cases of Chronic Hand Eczema in Japan (2017-2030)
  • Table 52 Gender-Specific Cases of CHE in Japan (2017-2030)
  • Table 53 Diagnosed Cases of Chronic Hand Eczema in Japan (2017-2030)
  • Table 54 Severity Specific Cases of CHE in Japan (2017-2030)
  • Table 55 Subgroup Specific Cases of CHE in Japan (2017-2030)
  • Table 56 Age-Specific Cases of CHE in Japan (2017-2030)
  • Table 57 Skin protection program based on evidence from clinical and experimental studies
  • Table 58 Treatment options for chronic HE
  • Table 59 Recommendations for the Prevention of Hand Eczema
  • Table 60 Recommendations for the Treatment of Hand Eczema
  • Table 61 Recommendations for the Systemic treatment of Chronic Hand Eczema
  • Table 62 Key cross of emerging drugs
  • Table 63 Delgocitinib, Clinical Trial Description, 2020
  • Table 64 ASN002, Clinical Trial Description, 2020
  • Table 65 Dupilumab, Clinical Trial Description, 2020
  • Table 66 Market Size of Chronic Hand Eczema in 7MM in USD Million (2017-2030)
  • Table 67 The US Market Size of Chronic Hand Eczema in USD Million (2017-2030)
  • Table 68 Market Size of CHE by therapies in the US in USD Million (2017-2030)
  • Table 69 Germany Market Size of Chronic Hand Eczema in USD Million (2017-2030)
  • Table 70 Market Size of CHE by therapies in Germany in USD Million (2017-2030)
  • Table 71 France Market Size of Chronic Hand Eczema in USD Million (2017-2030)
  • Table 72 Market Size of CHE by therapies in France in USD Million (2017-2030)
  • Table 73 Italy Market Size of Chronic Hand Eczema in USD Million (2017-2030)
  • Table 74 Market Size of CHE by therapies in Italy in USD Million (2017-2030)
  • Table 75 Spain Market Size of Chronic Hand Eczema in USD Million (2017-2030)
  • Table 76 Market Size of CHE by therapies in Spain in USD Million (2017-2030)
  • Table 77 UK Market Size of Chronic Hand Eczema in USD Million (2017-2030)
  • Table 78 Market Size of CHE by therapies in the UK in USD Million (2017-2030)
  • Table 79 Japan Market Size of Chronic Hand Eczema in USD Million (2017-2030)
  • Table 80 Market Size of CHE by therapies in Japan in USD Million (2017-2030)

List of Figures

  • Figure 1 Epidemiology and Market Methodology
  • Figure 2 Establish the diagnosis of acute hand dermatitis and chronic hand dermatitis (CHD)
  • Figure 3 Skin immune system
  • Figure 4 Photographic severity guide used in the physician's global assessment scoring
  • Figure 5 Flow chart for diagnosis of HE
  • Figure 6 Diagnostic chronic hand eczema (CHE) algorithm
  • Figure 7 Total Prevalent Cases of Chronic Hand Eczema in the 7MM (2017-2030)
  • Figure 8 Total Prevalent cases of Chronic Hand Eczema in the US (2017-2030)
  • Figure 9 Gender-Specific cases of CHE in the US (2017-2030)
  • Figure 10 Diagnosed Cases of Chronic Hand Eczema in the US (2017-2030)
  • Figure 11 Severity Specific Cases of CHE in the US (2017-2030)
  • Figure 12 Subgroup Specific Cases of CHE in the US (2017-2030)
  • Figure 13 Age-Specific Cases of CHE in the US (2017-2030)
  • Figure 14 Total Prevalent cases of Chronic Hand Eczema in Germany (2017-2030)
  • Figure 15 Gender-Specific cases of CHE in Germany (2017-2030)
  • Figure 16 Diagnosed Cases of Chronic Hand Eczema in Germany (2017-2030)
  • Figure 17 Severity Specific Cases of CHE in Germany (2017-2030)
  • Figure 18 Subgroup Specific Cases of CHE in Germany (2017-2030)
  • Figure 19 Age-Specific Cases of CHE in Germany (2017-2030)
  • Figure 20 Total Prevalent cases of Chronic Hand Eczema in France (2017-2030)
  • Figure 21 Gender-Specific cases of CHE in France (2017-2030)
  • Figure 22 Diagnosed Cases of Chronic Hand Eczema in France (2017-2030)
  • Figure 23 Severity Specific Cases of CHE in France (2017-2030)
  • Figure 24 Subgroup Specific Cases of CHE in the US (2017-2030)
  • Figure 25 Age-Specific Cases of CHE in France (2017-2030)
  • Figure 26 Total Prevalent cases of Chronic Hand Eczema in Italy (2017-2030)
  • Figure 27 Gender-Specific cases of CHE in Italy (2017-2030)
  • Figure 28 Diagnosed Cases of Chronic Hand Eczema in Italy(2017-2030)
  • Figure 29 Severity Specific Cases of CHE in Italy (2017-2030)
  • Figure 30 Subgroup Specific Cases of CHE in Italy (2017-2030)
  • Figure 31 Age-Specific Cases of CHE in Italy (2017-2030)
  • Figure 32 Total Prevalent cases of Chronic Hand Eczema in Spain (2017-2030)
  • Figure 33 Gender-Specific cases of CHE in Spain (2017-2030)
  • Figure 34 Diagnosed Cases of Chronic Hand Eczema in Spain (2017-2030)
  • Figure 35 Severity Specific Cases of CHE in Spain (2017-2030)
  • Figure 36 Subgroup Specific Cases of CHE in Spain (2017-2030)
  • Figure 37 Age-Specific Cases of CHE in Spain (2017-2030)
  • Figure 38 Total Prevalent cases of Chronic Hand Eczema in the UK (2017-2030)
  • Figure 39 Gender-Specific cases of CHE in the UK (2017-2030)
  • Figure 40 Diagnosed Cases of Chronic Hand Eczema in the UK (2017-2030)
  • Figure 41 Severity Specific Cases of CHE in the UK (2017-2030)
  • Figure 42 Subgroup Specific Cases of CHE in the UK (2017-2030)
  • Figure 43 Age-Specific Cases of CHE in the UK (2017-2030)
  • Figure 44 Total Prevalent cases of Chronic Hand Eczema in Japan (2017-2030)
  • Figure 45 Gender-Specific cases of CHE in Japan (2017-2030)
  • Figure 46 Diagnosed Cases of Chronic Hand Eczema in Japan (2017-2030)
  • Figure 47 Severity Specific Cases of CHE in Japan (2017-2030)
  • Figure 48 Subgroup Specific Cases of CHE in Japan (2017-2030)
  • Figure 49 Age-Specific Cases of CHE in Japan (2017-2030)
  • Figure 50 General Principles for the treatment of hand eczema
  • Figure 51 Treatment algorithm for hand eczema
  • Figure 52 Treatment algorithm for chronic hand eczema (CHE)
  • Figure 53 Unmet Needs for Chronic Hand Eczema
  • Figure 54 Market Size of Chronic Hand Eczema in 7MM in USD Million (2017-2030)
  • Figure 55 The Market Size of Chronic Hand Eczema in the US, USD Millions (2017-2030)
  • Figure 56 Market Size of CHE by therapies in the US in USD Million (2017-2030)
  • Figure 57 Market Size of Chronic Hand Eczema in Germany, USD Millions (2017-2030)
  • Figure 58 Market Size of CHE by therapies in Germany in USD Million (2017-2030)
  • Figure 59 Market Size of Chronic Hand Eczema in France, USD Millions (2017-2030)
  • Figure 60 Market Size of CHE by therapies in France in USD Million (2017-2030)
  • Figure 61 Market Size of Chronic Hand Eczema in Italy, USD Millions (2017-2030)
  • Figure 62 Market Size of CHE by therapies in Italy in USD Million (2017-2030)
  • Figure 63 Market Size of Chronic Hand Eczema in Spain, USD Millions (2017-2030)
  • Figure 64 Market Size of CHE by therapies in Spain in USD Million (2017-2030)
  • Figure 65 Market Size of Chronic Hand Eczema in the UK, USD Millions (2017-2030)
  • Figure 66 Market Size of CHE by therapies in the UK in USD Million (2017-2030)
  • Figure 67 Market Size of Chronic Hand Eczema in Japan, USD Millions (2017-2030)
  • Figure 68 Market Size of CHE by therapies in Japan in USD Million (2017-2030)
  • Figure 69 Market Drivers
  • Figure 70 Market Barriers
目次
Product Code: DIMI0369

DelveInsight's 'Chronic Hand Eczema (CHE)-Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the Chronic Hand Eczema (CHE), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic Hand Eczema (CHE) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted CHE symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Chronic Hand Eczema (CHE) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Chronic Hand Eczema (CHE) Disease Understanding and Treatment Algorithm

Chronic Hand Eczema (CHE) Overview

Hand eczema (HE) are non-infectious, inflammatory cutaneous lesions and belongs to the most common skin disorder exclusively localized to the hands. It is a highly prevalent, multi-etiological disease with a wide spectrum of severity and chronicity. In a substantial number of patients, HE can develop into a chronic condition, which remains active even after avoidance potentially damaging allergens and/or irritants.

Chronic Hand Eczema (CHE) has been defined as a long-lasting, relapsing course of Hand Eczema that is

  • Disease duration of at least 3 months or more than 3 flares within the last 12 months,
  • Unresponsive to standard treatment with emollients and topical corticosteroids for more than 3 months
  • The recurrence of symptoms two or more times within a year despite adequate treatment.
  • No dominating active severe skin diseases or acute skin infections

CHE as an anatomoclinic syndrome with multifactorial origins that is not restricted to allergic or orthoergic origin. Clinical features include localization of eczema to the hands and fingers, including dryness, erythema, edema, hyperkeratosis, scaling, lichenification, vesiculation/blistering, fissures, pruritus, and pain. It is typically a dynamic condition extending over the years, and its morphology may change with time, both clinically and histologically. Erythema, edema, and vesicles are characteristic of acute eczema, whereas infiltration, hyperkeratosis, and fissures are seen in chronic eczema. It has significant morbidity and lost earnings and has severe negative impacts on the social and psychosocial aspects of patients' lives.

Chronic Hand Eczema (CHE) is one of the most common dermatological diseases, with a varied time of onset in varying clinical manifestations. The pathogenesis of HE is multifactorial and involves a variety of exogenous (i.e. irritants, allergens, pathogens) and endogenous components (i.e. intrinsic barrier defects, dysregulation of the skin microbiome, and immune dysregulation). Subsequently, subtypes are the result of shared and distinct pathways.

Chronic Hand Eczema (CHE) Diagnosis and Treatment

The classification of HE has been contentious since the different subgroups are classified according to etiology as well as morphology. Consensus on classification is important in order to obtain a mutual understanding of sub-diagnoses. A universally accepted classification system to differentiate the subtypes with dedicated epidemiological studies is the current unmet need.

Multiple diagnostic procedures may be needed in each individual case. The important investigations include standard patch testing, skin prick tests, microbial tests, cutaneous biopsies, total and differential leucocyte count evidencing eosinophilia, serum IgE level, skin biopsy, potassium hydroxide preparation, fungal and bacterial cultures, Gram staining, radioallergosorbent test (RAST), and in vitro lymphocyte stimulation test.

Due to the high incidence and prevalence of this pathology, it has enormous socioeconomic consequences and a massive impact on patients' quality of life. The increasingly complex and industrialized environment of the 21st century has made it all the more important to find the exact etiology of the disease and to use appropriate preventive and treatment measures.

Chronic hand eczema may require a stage-wise treatment approach starting with avoiding allergens to the frequent use of barrier creams, combining with topical, physical (UV light) and systemic options. Since the spectrum of CHE severity varies widely, individual therapy should be based on an objective and subjective assessment. Even though, Steroids are standard therapy, about half of patients fail to respond to treatment and become chronic. Treatment options for CHE patients are ample, but their efficacy is limited

Chronic Hand Eczema (CHE) Epidemiology

The CHE symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

According to DelveInsight, the total prevalent cases of Chronic Hand Eczema (CHE) in the 7MM was found to be 4,229,215 in 2017. The prevalence of Chronic Hand Eczema (CHE) in the 7MM is expected to increase during the study period of 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenarios of Chronic Hand Eczema (CHE) in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030. The epidemiology has segmented into Total Prevalent cases of Chronic Hand Eczema, Gender-Specific cases of Chronic Hand Eczema, Diagnosed Cases of Chronic Hand Eczema, and Age-Specific cases of Chronic Hand Eczema, Severity Specific Cases of Chronic Hand Eczema and Subgroup Specific Cases of Chronic Hand Eczema.

As per the National Eczema Association, Hand Eczema/Hand Dermatitis is a very common condition affecting up to 10% of the population. Chronic Hand Eczema is estimated to occur in 5-7% of patients with Hand Eczema. Among these, Severe chronic HE has a major adverse impact on economic and social functions.

Country Wise- Chronic Hand Eczema (CHE) Epidemiology

The epidemiology segment also provides the Chronic Hand Eczema (CHE) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Chronic Hand Eczema (CHE) Drug Chapters

The drug chapter segment of the Chronic Hand Eczema (CHE) report encloses the detailed analysis of CHE marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Chronic Hand Eczema (CHE) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Chronic Hand Eczema (CHE) Marketed Drugs

Toctino: Alitretinoin

It acts as a pan-agonist of retinoid receptors which was developed by Basilea Pharmaceutica and has been specifically developed for severe CHE. It is only available in the EU, Canada and other regions for the treatment of severe chronic hand eczema (CHE), refractory to treatment with a potent topical corticosteroid. The product is widely accepted and included in the NICE guidelines to treat the CHE. However, there is no approved systemic therapy available in the US and Japan for the treatment of corticosteroid resistant CHE.

Products detail in the report…

Chronic Hand Eczema (CHE) Emerging Drugs

To counter the current unmet needs, the market is hoping to provide better treatment options for CHE. With the continuous efforts in research and development, few companies are developing therapies such as LEO Pharma, Asana Biosciences, Afecta Therapeutics, Regeneron Pharmaceuticals/Sanofi, NUVO research, and Aralez Pharmaceuticals. Post 2023 the market is expected to witness rapid growth due to the expected launch of emerging therapies, with a novel class of drugs such as Delgocitinib (LEO Pharma/ Japan Tobacco), ASN002 (Asana Biosciences), Dupilumab (Regeneron/Sanofi). These drugs are targeting most of the refractory pool of the CHE.

Products detail in the report…

Chronic Hand Eczema (CHE) Market Outlook

The Chronic Hand Eczema (CHE) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Chronic Hand Eczema (CHE) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Chronic Hand Eczema (CHE) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Chronic Hand Eczema (CHE) market in 7MM is expected to change in the study period 2017-2030.

The onset of chronic illness has been described as a 'biographical disruption', where individuals actively attempt to adapt to the required treatment regimen. Medication adherence is considered low within dermatology. On the other hand, chronic hand eczema requires both medication adherence as well as preventive measures. Adequate treatment and subsequent prevention of relapses by identifying the aggravating factor with health education and support have consideration in the treatment.

The most prescribed treatments are emollients/moisturizers and topical corticosteroids. Although hand eczema is complex, simple solutions are offered; the simplicity of using emollients as preventive measures, apparently contradicted the complexity. These are used widely as the first-line interventions to treat the mild to moderate HE condition in order to prevent chronic conversion.

Topical corticosteroids are a first-line therapy and the mainstay of treatment for hand eczema. However, potent systemic corticosteroids can lead to long-term systemic complications, thus the usage would optimally be decreased to allow for steroid-free days to decrease the risk of developing side effects.

Topical calcineurin inhibitors (TCI) such as tacrolimus and pimecrolimus are useful to treat the remission of eczema in a combination of topical corticosteroids can be used for longer periods.

Secondary infection often treated with systemic antibiotics; agents with anti-inflammatory action are especially useful.

Long-term chronic severe cases of hand eczema can be very difficult to treat successfully. The off-license use of systemic treatments is indicated in the CHE, the one that persists despite 8 weeks of topical treatment and good adherence. A range of immunosuppressants, including cyclosporine, azathioprine, and methotrexate, have been used off-label for severe eczema, even though there is a relative lack of evidence of effectiveness. The severe chronic hand eczema market is filled with the prescription of these depending on the severity and presentation.

The disparities between the use of treatments as prescribed, severity, satisfaction and severe impact on the quality of life need a closer look in market-defining. Among these prescribed treatments, patients are concerned about the side effects or have a negative phobia about treatments. Despite care, 1 in 2 CHE patients' lives with their symptoms every day, in recurring cycles. Patients with severe CHE have had few treatment options if topical corticosteroids have failed to improve their situation. Given the limitations of current treatments and the lack of consensus between prescribers, there is a clear, unmet need, for effective long-term management of severe CHE that is unresponsive to potent topical corticosteroids.

Key Findings

This section includes a glimpse of the Chronic Hand Eczema (CHE) market in 7MM. The market size of CHE in the seven major markets is expected to be USD 728.41 Million in 2017.

The United States Market Outlook

This section provides the total Chronic Hand Eczema (CHE) market Size and market Size by therapies in the United States.

The United States accounts for the highest market size of CHE in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Chronic Hand Eczema (CHE) market Size and market Size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Alitretinoin is the only drug that has been specifically developed for the indication of CHE and got approval in multiple European countries and is widely accepted and included in the NICE guidelines to treat the CHE. Along with the current treatment, expected launch of the emerging therapies may increase the market share further during the forecast period [2020-2030].

Japan Market Outlook

The total Chronic Hand Eczema (CHE) market Size and market Size by therapies in Japan are also mentioned.

Chronic Hand Eczema (CHE) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Chronic Hand Eczema (CHE) market uptake by drugs; patient uptake by therapies; and sales of each drug.

Currently, the current market size for the initial stage Chronic Hand Eczema majorly includes Topical corticosteroids, calcineurin inhibitors, phototherapy, and other radiation therapies. For the relapse or recurrent conditions, systemic therapies with short-term oral corticosteroids, immunosuppressants (azathioprine, methotrexate, cyclosporine, mycophenolate mofetil), and Oral retinoids are dominating the market. Toctino (alitretinoin) of the Basilea Pharmaceutica/ Stiefel Laboratories is the only approved systemic therapy available in the multiple European countries for the treatment of corticosteroid-resistant CHE.

The primary unmet need for the CHE treatment market is the limited availability of approved therapies. To meet this, companies have shifted their focus towards the development of systemic therapies by targeting the various specific mediators involved in the pathogenesis of HE. Along with these actionable targets, the overall market size of off-label therapies will experience a modest rise in the US until 2023. However, post 2023 the market is expected to witness rapid growth due to the expected launch of emerging therapies.

Chronic Hand Eczema (CHE) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Chronic Hand Eczema (CHE) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Chronic Hand Eczema (CHE) emerging therapies.

This segment of the Chronic Hand Eczema (CHE) report encloses the detailed analysis of marketed drugs and the Middle stage (Phase-II and Phase-I) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Reimbursement Scenario in CHE

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

The future market of CHE should invest in research to develop new treatments in order to provide better therapies to manage the disease more effectively and ultimately to cure it. Better reimbursement policies would reduce this collateral burden in patient's lives by providing financial support from health insurance. In the US, the health insurance covering most of CHE patients through private self-pay and/or employer-sponsored health insurance, or a form of public insurance, i.e., Medicare, Medicaid, and Veterans Affairs.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Chronic Hand Eczema (CHE) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Hand Eczema (CHE) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Chronic Hand Eczema (CHE) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of CHE, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Chronic Hand Eczema (CHE) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Hand Eczema (CHE) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Chronic Hand Eczema (CHE) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Hand Eczema (CHE) market

Report Highlights

  • In the coming years, Chronic Hand Eczema (CHE) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hand Eczema (CHE) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for CHE. Launch of emerging therapies will significantly impact the Chronic Hand Eczema (CHE) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for CHE
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chronic Hand Eczema (CHE) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Chronic Hand Eczema (CHE) Pipeline Analysis
  • Chronic Hand Eczema (CHE) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic Hand Eczema (CHE) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Chronic Hand Eczema (CHE) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Chronic Hand Eczema (CHE) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What were the Chronic Hand Eczema (CHE) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Chronic Hand Eczema (CHE) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Chronic Hand Eczema (CHE)market Size during the forecast period (2017-2030)?
  • At what CAGR, the Chronic Hand Eczema (CHE) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Chronic Hand Eczema (CHE) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Chronic Hand Eczema (CHE) market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the CHE?
  • What is the historical Chronic Hand Eczema (CHE) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Chronic Hand Eczema (CHE) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CHE?
  • Out of all 7MM countries, which country would have the highest prevalent population of Chronic Hand Eczema (CHE) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Chronic Hand Eczema (CHE) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Chronic Hand Eczema (CHE) in the USA, Europe, and Japan?
  • What are the Chronic Hand Eczema (CHE) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of CHE?
  • How many therapies are developed by each company for the treatment of CHE?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of CHE?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Hand Eczema (CHE) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Hand Eczema (CHE) and their status?
  • What are the key designations that have been granted for the emerging therapies for CHE?
  • What are the global historical and forecasted market of CHE?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Chronic Hand Eczema (CHE) market
  • To understand the future market competition in the Chronic Hand Eczema (CHE) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Hand Eczema (CHE) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in delveInsight strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Hand Eczema (CHE) market
  • To understand the future market competition in the Chronic Hand Eczema (CHE) market

Table of Contents

1. Key Insights

2. Executive summary

3. Chronic Hand Eczema: Market Overview at a Glance

  • 3.1. Total Market Share (%) Distribution of Chronic Hand Eczema in 2017
  • 3.2. Total Market Share (%) Distribution of Chronic Hand Eczema in 2030

4. Epidemiology and Market Methodology

5. Organizations

6. Chronic Hand Eczema: Disease Background and Overview

  • 6.1. Introduction
  • 6.2. Classification
  • 6.3. Etiology
  • 6.4. Symptoms
  • 6.5. Risk Factors
  • 6.6. Pathogenesis
  • 6.7. Defining CHE Severity and Therapeutic Response
  • 6.8. Diagnosis
    • 6.8.1. Differential diagnosis
    • 6.8.2. Guidelines for Diagnosis of hand eczema - European Society of Contact Dermatitis (ESCD)
  • 6.9. Diagnostic Algorithm

7. Epidemiology and Patient Population

  • 7.1. Key Findings

8. Total Prevalent Cases of Chronic Hand Eczema in 7MM

9. United States Epidemiology

  • 9.1. Assumptions and Rationale
    • 9.1.1. Total Prevalent Cases of Chronic Hand Eczema in the United States
    • 9.1.2. Gender-Specific Cases of Chronic Hand Eczema in the United States
    • 9.1.3. Diagnosed Cases of Chronic Hand Eczema in the United States
    • 9.1.4. Severity Specific Cases of CHE in the United States
    • 9.1.5. Subgroup-Specific Cases of CHE in the United States
    • 9.1.6. Age-Specific Cases of CHE in the United States

10. EU5 Epidemiology

  • 10.1. Germany Epidemiology
    • 10.1.1. Assumptions and Rationale
    • 10.1.2. Total Prevalent Cases of Chronic Hand Eczema in Germany
    • 10.1.3. Gender-Specific Cases of Chronic Hand Eczema in Germany
    • 10.1.4. Diagnosed Cases of Chronic Hand Eczema in Germany
    • 10.1.5. Severity Specific Cases of CHE in Germany
    • 10.1.6. Subgroup-Specific Cases of CHE in Germany
    • 10.1.7. Age-Specific Cases of CHE in Germany
  • 10.2. France Epidemiology
    • 10.2.1. Assumptions and rationale
    • 10.2.2. Total Prevalent Cases of Chronic Hand Eczema in France
    • 10.2.3. Gender-Specific Cases of Chronic Hand Eczema in France
    • 10.2.4. Diagnosed Cases of Chronic Hand Eczema in France
    • 10.2.5. Severity Specific Cases of CHE in France
    • 10.2.6. Subgroup-Specific Cases of CHE in the United States
    • 10.2.7. Age-Specific Cases of CHE in France
  • 10.3. Italy Epidemiology
    • 10.3.1. Assumptions and Rationale
    • 10.3.2. Total Prevalent Cases of Chronic Hand Eczema in Italy
    • 10.3.3. Gender-Specific Cases of Chronic Hand Eczema in Italy
    • 10.3.4. Diagnosed Cases of Chronic Hand Eczema in Italy
    • 10.3.5. Severity Specific Cases of CHE in Italy
    • 10.3.6. Subgroup-Specific Cases of CHE in Italy
    • 10.3.7. Age-Specific Cases of CHE in Italy
  • 10.4. Spain Epidemiology
    • 10.4.1. Assumptions and Rationale
    • 10.4.2. Total Prevalent Cases of Chronic Hand Eczema in Spain
    • 10.4.3. Gender-Specific Cases of Chronic Hand Eczema in Spain
    • 10.4.4. Diagnosed Cases of Chronic Hand Eczema in Spain
    • 10.4.5. Severity Specific Cases of CHE in Spain
    • 10.4.6. Subgroup-Specific Cases of CHE in Spain
    • 10.4.7. Age-Specific Cases of CHE in Spain
  • 10.5. United Kingdom Epidemiology
    • 10.5.1. Assumptions and Rationale
    • 10.5.2. Total Prevalent Cases of Chronic Hand Eczema in the UK
    • 10.5.3. Gender-Specific Cases of Chronic Hand Eczema in the UK
    • 10.5.4. Diagnosed Cases of Chronic Hand Eczema in the UK
    • 10.5.5. Severity Specific Cases of CHE in the UK
    • 10.5.6. Subgroup-Specific Cases of CHE in the UK
    • 10.5.7. Age-Specific Cases of CHE in the UK

11. Japan Epidemiology

  • 11.1. Assumptions and Rationale
    • 11.1.1. Total Prevalent Cases of Chronic Hand Eczema in Japan
    • 11.1.2. Gender-Specific Cases of Chronic Hand Eczema in Japan
    • 11.1.3. Diagnosed Cases of Chronic Hand Eczema in Japan
    • 11.1.4. Severity Specific Cases of CHE in Japan
    • 11.1.5. Subgroup-Specific Cases of CHE in Japan
    • 11.1.6. Age-Specific Cases of CHE in Japan

12. Prevention and Treatment of Chronic Hand Eczema

  • 12.1. Prevention
  • 12.2. Treatment
  • 12.3. Consensus statement for the management of chronic hand eczema - British Association of Dermatologists
  • 12.4. Prevention and Treatment of hand eczema - European Society of Contact Dermatitis (ESCD) guidelines
  • 12.5. Treatment algorithm for Chronic Hand Eczema

13. Unmet Needs

14. Marketed Drugs

  • 14.1. Toctino: Basilea Pharmaceutica/ Stiefel Laboratories
    • 14.1.1. Product Description
    • 14.1.2. Regulatory Milestones
    • 14.1.3. Other Development Activities
    • 14.1.4. Safety and Efficacy
    • 14.1.5. Product Profile

15. Emerging Therapies

  • 15.1. Key Cross Competition
  • 15.2. Delgocitinib: LEO Pharma/Japan Tobacco
    • 15.2.1. Product Description
    • 15.2.2. Other Developmental Activities
    • 15.2.3. Clinical Development
    • 15.2.4. Safety and Efficacy
    • 15.2.5. Product Profile
  • 15.3. ASN002: Asana Biosciences
    • 15.3.1. Drug Description
    • 15.3.2. Other Developmental Activities
    • 15.3.3. Clinical Development
    • 15.3.4. Safety and Efficacy
    • 15.3.5. Product Profile
  • 15.4. Dupilumab: Regeneron Pharmaceuticals/Sanofi
    • 15.4.1. Product Description
    • 15.4.2. Other Developmental Activities
    • 15.4.3. Clinical Development
    • 15.4.4. Safety and Efficacy
    • 15.4.5. Product Profile

16. Chronic Hand Eczema: 7MM Market Analysis

    • 16.1.1. Key Findings
    • 16.1.2. Market Size of Chronic Hand Eczema in 7MM

17. United States: Market Outlook

  • 17.1. United States Market Size
    • 17.1.1. The total market size of Chronic Hand Eczema
    • 17.1.2. Market Size of Chronic Hand Eczema by Therapies in the US

18. EU-5 countries: Market Outlook

  • 18.1. Germany Market Size
    • 18.1.1. The total market size of Chronic Hand Eczema
    • 18.1.2. Market Size of Chronic Hand Eczema by Therapies in Germany
  • 18.2. France Market Size
    • 18.2.1. The total market size of Chronic Hand Eczema
    • 18.2.2. Market Size of Chronic Hand Eczema by Therapies in France
  • 18.3. Italy Market Size
    • 18.3.1. The total market size of Chronic Hand Eczema
    • 18.3.2. Market Size of Chronic Hand Eczema by Therapies in Italy
  • 18.4. Spain Market Size
    • 18.4.1. The total market size of Chronic Hand Eczema
    • 18.4.2. Market Size of Chronic Hand Eczema by Therapies in Spain
  • 18.5. United Kingdom Market Size
    • 18.5.1. The total market size of Chronic Hand Eczema
    • 18.5.2. Market Size of Chronic Hand Eczema by Therapies in the UK

19. Japan Market Outlook

  • 19.1. Japan Market Size
    • 19.1.1. The total market size of Chronic Hand Eczema
    • 19.1.2. Market Size of Chronic Hand Eczema by Therapies in Japan

20. Reimbursement policies

  • 20.1. Access and Reimbursement Overview for Current and Future Therapies
    • 20.1.1. Current Therapies
    • 20.1.2. Future Therapies

21. Market Drivers

22. Market Barriers

23. SWOT Analysis

24. Case Report

  • 24.1. A Case Report of CHE
  • 24.2. Case II

25. KOL Views

26. Appendix

27. Report Methodology

28. DelveInsight Capabilities

29. Disclaimer

30. About DelveInsight